Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1/2a investigator-initiated study targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.
Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.
Click here to view our Corporate Presentation.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Corporate Events & Presentations
Sep 22, 2021 at 4:30 PM EDT
Webinar Featuring Expert Overview from Key Opinion Leaders
Sep 22, 2021
3rd Annual RAS Targeted Drug Development Summit 11:30 a.m. ETPhase 1/2 Trial of Rigosertib & Nivolumab in KRAS-Mutated NSCLC in 2nd+ Line presented by Rajwanth Veluswamy, MD MSCR, Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, NYC